
Court sides with Amgen in Sandoz’ challenge over patent on Enbrel
pharmafile | August 12, 2019 | News story | Sales and Marketing | Enbrel, IP, Novartis Amgen, court, patent, pharma
A US court has sided with Amgen in a legal battle over the patent on blockbuster rheumatoid arthritis drug Enbrel.
US District Judge Claire Cecchi in Newark, New Jersey, upheld two patents on Amgen’s Enbrel on Friday 9 August.
The decision comes after a challenge from Swiss multinational Novartis which is seeking to launch a generic version of the drug.
Novartis’ generics unit Sandoz claimed the patents covering Enbrel’s active ingredients until 2029 should not have been granted because their concepts were already covered in previous patents.
The decision was a relief to investors who pushed Amgen shares up by 6% on closing. Enbrel generated $4.8 billion in sales last year.
Amgen CEO Robert Bradway commented: “protecting intellectual property is critical to incentivise innovation and the large investments in R&D that are required to bring new medicines to patients and fully develop their therapeutic potential.”
Carol Lynch, president of Sandoz US and head of North America, commented: “Sandoz respectfully disagrees with the Court’s ruling, which prevents us from launching an additional treatment option for patients with autoimmune and inflammatory diseases.”
Louis Goss
Related Content

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence
LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

Johnson & Johnson announces successful results from trial for myeloma treatment
Global healthcare company, Johnson & Johnson, announced that analysis of its Darzalex (daratumumab) therapy showed …

Bend Bioscience adds commercial spray drying facility to Georgia site
Bend Bioscience has announced the addition of a commercial-scale spray dryer and a Gerteis dry …






